Angiogenesi
Gli inibitori dell'angiogenesi sono composti che interferiscono con la formazione di nuovi vasi sanguigni, un processo cruciale nella crescita e metastasi del cancro. Inibendo l'angiogenesi, questi composti possono limitare l'apporto di sangue ai tumori, rallentandone o arrestando la crescita. Gli inibitori dell'angiogenesi sono fondamentali nella ricerca sul cancro e nello sviluppo terapeutico, offrendo approfondimenti sui meccanismi di progressione tumorale e potenziali trattamenti per il cancro e altre malattie legate all'angiogenesi. Presso CymitQuimica, offriamo un'ampia gamma di inibitori dell'angiogenesi di alta qualità per supportare le tue ricerche in oncologia e biologia vascolare.
Sottocategorie di "Angiogenesi"
- BTK(157 prodotti)
- Bcr-Abl(113 prodotti)
- EGFR(596 prodotti)
- FAK(72 prodotti)
- FLT(88 prodotti)
- Recettore del fattore di crescita dei fibroblasti (FGFR)(180 prodotti)
- JAK(246 prodotti)
- PDGFR(126 prodotti)
- RAAS(90 prodotti)
- Src(81 prodotti)
- Syk(37 prodotti)
- Trombina(52 prodotti)
- VDA(2 prodotti)
- VEGFR(250 prodotti)
Mostrare 6 più sottocategorie
Trovati 2002 prodotti di "Angiogenesi"
Ordinare per
Purezza (%)
0
100
|
0
|
50
|
90
|
95
|
100
FLT3-IN-29
<p>FLT3-IN-29 (Compound MY-10) is an FLT3 inhibitor with IC50 values of 6.5 nM and 10.3 nM for FLT3-ITD and FLT3-D835Y mutants, respectively. It induces cell cycle arrest at the G0/G1 phase and effectively triggers apoptosis (Apoptosis). Additionally, FLT3-IN-29 reduces reactive oxygen species (ROS) and mitochondrial membrane potential (MMP), displaying anti-leukemic properties.</p>Formula:C25H30N6O2Colore e forma:SolidPeso molecolare:446.545PROTAC FLT3/CDKs degrader-1
<p>PROTACFLT3/CDKs degrader-1 (Compound C3) is an agent that degrades cyclin-dependent kinase (CDK2 with a DC50 of 18.73 nM) and FMS-like tyrosine kinase 3 (FLT3). It induces differentiation in HL-60 cells, achieving a 72.77% differentiation rate at 6.25 nM, and inhibits proliferation of acute myeloid leukemia (AML) cells, with an IC50 ranging from 2.9 to 37 nM. PROTACFLT3/CDKs degrader-1 demonstrates potential for improving the treatment of AML.</p>Formula:C40H42N12O5Peso molecolare:770.34011Lyso-Monosialoganglioside GM3
CAS:<p>Lyso-Monosialoganglioside GM3 (Lyso-GM3) is an analog of Ganglioside GM3 with antitumor properties. It inhibits the increase in EGFR kinase activity induced by EGF in A431 epithelial cancer cells.</p>Formula:C41H74N2O20Colore e forma:SolidPeso molecolare:915.028AKN-028
CAS:<p>AKN-028 is an orally active and potent FLT3 tyrosine kinase inhibitor ( IC 50 = 6 nM). AKN-028 causes dose-dependent inhibition of FLT3 autophosphorylation.</p>Formula:C17H14N6Purezza:99.88%Colore e forma:SolidPeso molecolare:302.33SNIPER(ABL)-024
CAS:SNIPER(ABL)-024, a compound that conjugates GNF5 (ABL inhibitor) to an LCL161 derivative (IAP ligand) via a linker, effectively reduces BCR-ABL protein levels,Formula:C52H61F3N8O9SPurezza:98%Colore e forma:SolidPeso molecolare:1031.15EGFR-IN-15
CAS:EGFR-IN-15 (compound I-005) is a potent EGFR inhibitor, exhibiting an IC50 value of 4 nM. This compound holds potential for oncological research applications.Formula:C24H25BrN6O2Colore e forma:SolidPeso molecolare:509.408EGFR-IN-83
<p>EGFR-IN-83 (Compound 9), an EGFR inhibitor with an IC50 of 2.53 nM, exhibits antiproliferative effects on MCF-7 and MDA-MB-231 cell lines, with respective IC50</p>Formula:C22H17F3N4OPurezza:98%Colore e forma:SolidPeso molecolare:410.39PROTAC BCR-ABL1 ligand 1
CAS:<p>GMB-475 is a PROTAC ligand targeting BCR-ABL1 for degradation via E3 ligase recruitment.</p>Formula:C17H12F3N3O2Colore e forma:SoildPeso molecolare:347.29MC-Val-Cit-PAB-Amide-TLR7 agonist 4 Conjugate
CAS:MC-Val-Cit-PAB-Amide-TLR7 agonist 4 Conjugate is a conjugate formed by linking MC-Val-Cit-PAB-Amide and TLR7 agonist 4, useful for cancer research.Formula:C52H72N12O11Purezza:97.70%Colore e forma:SolidPeso molecolare:1041.2AT-533
CAS:AT-533 inhibits Hsp90, HSV, hinders HIF-1α/VEGF/VEGFR-2, Erk1/2, FAK, Akt/mTOR/p70S6K, and blocks tumor growth, angiogenesis, and HUVEC activities.Formula:C23H30N4O3Purezza:99.67%Colore e forma:SoildPeso molecolare:410.51AD57
CAS:<p>AD57 is a potent inhibitor of both c-Src and Abl with IC50 of 0.025 μM and 0.041 μM, respectively.</p>Formula:C22H20F3N7OPurezza:99.05%Colore e forma:SoildPeso molecolare:455.44Ibrutinib-biotin
CAS:<p>Ibrutinib-biotin probe links Ibrutinib to biotin, with IC50 0.755-1.02 nM for BTK (patent WO2014059368A1).</p>Formula:C56H80N12O9SPurezza:98%Colore e forma:SolidPeso molecolare:1097.39TLT8
TLT8 is a ByeTAC protein degrader that targets BTK. It induces BTK degradation by non-covalently binding to Rpn-13 and BTK. TLT8 is applicable in research on chronic lymphocytic leukemia.Colore e forma:Odour SolidALK protein ligand-1
CAS:ALK protein ligand-1 (Compound A1) is an ALK protein ligand, acting as a ligand for the target protein in PROTACs, demonstrating inhibitory effects on ALK. It is also useful in the synthesis of AP-1.Formula:C24H29ClN6O3SColore e forma:SolidPeso molecolare:517.043EGFR-TK-IN-5
EGFR-TK-IN-5 (Compound NCE 2) is a thiazolyl pyrazoline derivative with significant inhibitory activity and stability against EGFR. It is applicable in tumor research.Formula:C26H20ClFN4OSColore e forma:SolidPeso molecolare:490.98BTK ligand-14
BTKligand-14 is a PROTAC-targeting ligand for BTK, suitable for the synthesis of FDU73.Colore e forma:Odour SolidSimotinib hydrochloride
CAS:Simotinib hydrochloride: selective oral EGFR inhibitor, IC50 19.9 nM, potent anticancer agent.Formula:C25H27Cl2FN4O4Colore e forma:SolidPeso molecolare:537.41PROTAC EGFR degrader 6
CAS:<p>PROTAC EGFR degrader 6 effectively degrades EGFR Del19 in HCC827 cells (DC50=45.2 nM) and induces apoptosis and G1 arrest.</p>Formula:C49H57FN12O5Colore e forma:SolidPeso molecolare:913.05MP-RM-1
MP-RM-1 is a selective murine monoclonal antibody inhibitor that targets the human epidermal growth factor receptor 3 (ErbB-3). It blocks ErbB-3 activation induced by neuregulin 1 (NRG-1β), facilitates ErbB-3 internalization and degradation, and inhibits downstream signaling pathways like PI3K-Akt. MP-RM-1 shows potential for research on ErbB-3-overexpressing solid tumors such as breast cancer, melanoma, and prostate cancer.Colore e forma:Odour LiquidEGFR-IN-144
<p>EGFR-IN-144 (Compound 4B) inhibits EGFR (IC50=0.639 µg/mL) and tubulin polymerization (IC50=7.339 µg/mL). It exhibits cytotoxicity in various cancer cells with a GI50 at the nanomolar level. EGFR-IN-144 reduces the expression of mTOR, TNF-α, and IL-6, causes G1/S phase cell cycle arrest, and induces apoptosis.</p>Formula:C20H17Cl2N3O3Colore e forma:SolidPeso molecolare:418.273RR-src
CAS:Tyrosine kinase substrate peptideFormula:C64H106N22O21Purezza:98%Colore e forma:Lyophilized PowderPeso molecolare:1519.66SJ1008030 formic
SJ1008030 (compound 8) formic is a selective JAK2 degrader within the PROTAC class, demonstrating efficacy in inhibiting MHH-CALL-4 leukemia cell growth with anFormula:C43H45N13O9SPurezza:98%Colore e forma:SolidPeso molecolare:919.96ALK-IN-13
CAS:<p>ALK-IN-13 is an ALK inhibitor.</p>Formula:C29H39ClN7O2PColore e forma:SolidPeso molecolare:584.1Axltide
CAS:Axltide mimics mouse Insulin receptor substrate 1, amino acids 979-989 with sequence KKSRGDYMTMQIG.Formula:C63H107N19O20S2Purezza:98%Colore e forma:SolidPeso molecolare:1514.77DSPE-PEG2000-GE11
<p>DSPE-PEG2000-GE11 is a PEG compound composed of DSPE and an EGFR-targeting peptide (GE11). GE11 is applicable for cancer cells that overexpress EGFR. DSPE-PEG2000-GE11 is utilized in drug delivery.</p>Colore e forma:Odour SolidEGFR-IN-78
<p>EGFR-IN-78 (compound A5), a 2-aminopyrimidine derivative, serves as a reversible EGFR C797S-TK inhibitor and an apoptosis inducer.</p>Formula:C23H32BrN7O2SPurezza:98%Colore e forma:SolidPeso molecolare:550.51Duligotuzumab
CAS:Duligotuzumab is a dual-targeting anti-EGFR/HER3 mAb that blocks signaling and induces ADCC for tumors with poor prognosis.Purezza:97.7% (SDS-PAGE); 96.3% (SEC-HPLC) - ≥95% (SDS-PAGE); 95.19% (SEC-HPLC)Colore e forma:LiquidBW710
<p>BW710 is an orally active inhibitor specifically targeting fibroblast growth factor receptor 2 (FGFR2). It effectively inhibits the proliferation of BaF3-FGFR2 cells with an IC50 value of 2.8 nM. BW710 completely suppresses FGFR2 enzymatic activity and demonstrates selectivity among 75 tyrosine kinases, including FGFR1, FGFR3, and FGFR4, at a 1 μM concentration. Additionally, BW710 impedes FGFR2 signaling and selectively inhibits the proliferation of cancer cells driven by FGFR2. It exhibits promising pharmacokinetic properties, with an oral bioavailability of 29% in mice.</p>Formula:C28H29FN6O2SColore e forma:SolidPeso molecolare:532.63(R)-3-Hydroxy Midostaurin
CAS:(R)-3-Hydroxy Midostaurin: potent kinase inhibitor, major midostaurin metabolite via CYP3A4, potential AML treatment.Formula:C35H30N4O5Purezza:98%Colore e forma:SolidPeso molecolare:586.648Mal-VC-PAB-(N-Me-amide-C3)-ADU-S100 triethylamine
CAS:Mal-VC-PAB-(N-Me-amide-C3)-ADU-S100 triethylamine: an ISAC with anti-HER2, STING agonist ADU-S100, linker; for cancer research.Formula:C51H65N17O19P2S2·xC6H15NColore e forma:SolidPeso molecolare:1447.44Lyn peptide inhibitor
CAS:Inhibits Lyn kinase, blocks IL-5 receptor, prevents eosinophil differentiation and reduces asthma-related inflammation in mice.Formula:C115H184N30O24Purezza:98%Colore e forma:SolidPeso molecolare:2370.91Varlitinib Tosylate
CAS:Varlitinib Tosylate is a selective and potent inhibitor of ErbB1(EGFR) and ErbB2(HER2).Formula:C36H35ClN6O8S3Purezza:98%Colore e forma:SolidPeso molecolare:811.34Src Inhibitor 4
<p>Src Inhibitor4 (Compound 18) is a derivative of KX-01 and functions as a Src inhibitor. It effectively disrupts tumor cells, damages microtubules, and induces cell cycle arrest, apoptosis, and immunogenic cell death. After introducing phenol or aniline functional groups, Src Inhibitor4 serves as a payload conjugation site for antibody-drug conjugates, showcasing antitumor activity.</p>Formula:C33H34N4O3Colore e forma:SolidPeso molecolare:534.648EGFR/BRAFV600E-IN-3
EGFR/BRAFV600E-IN-3 is an inhibitor targeting EGFR, BRAFV600E, and EGFRT790M with IC50 values of 57 nM, 68 nM, and 9.70 nM, respectively.Formula:C25H18N4O3Purezza:98%Colore e forma:SolidPeso molecolare:422.44DD 03-171
CAS:<p>Potent BTK Degrader, IC50=5.1nM, CRBN-dependent, suppresses MCL; degrades Ibrutinib-resistant BTK, no kinases binding, reduces tumors in models.</p>Formula:C55H62N10O8Colore e forma:SolidPeso molecolare:991.163EGFR/COX-2-IN-1
<p>EGFR/COX-2-IN-1 is an EGFR/COX-2 inhibitor that effectively targets EGFRWT, EGFRT790M, COX-1, and COX-2 with IC50 values of 0.12, 0.076, 20.1, and 1.52 μM, respectively. It inhibits MCF-7, HT-29, and A-549 cells with IC50 values of 1.20, 5.14, and 14.81 μM, respectively. The compound induces apoptosis by upregulating Bax protein and downregulating Bcl-2 protein levels. Additionally, EGFR/COX-2-IN-1 significantly increases the proportion of cells in the G2/M phase in MCF-7 cells, demonstrating a broad-spectrum antitumor effect.</p>Formula:C20H17FN6O2S2Colore e forma:SolidPeso molecolare:456.52JAK1/STAT3-IN-1
JAK1/STAT3-IN-1 (compound 4f) functions as an anti-atopic dermatitis (AD) agent by inhibiting the JAK1/STAT3 signaling pathway. It has an IC50 value of 2.17 μM for inhibiting NO production. Additionally, JAK1/STAT3-IN-1 improves skin conditions in AD-like mice by reducing inflammatory infiltration, suppressing the expression of p-JAK1/JAK1 and p-STAT3/STAT3, and alleviating the hyperimmune response induced by MC903 (Calcipotriol).Formula:C30H33FN4O3SColore e forma:SolidPeso molecolare:548.67Si5-N14
CAS:Si5-N14 is a key component of siloxane-linked lipid nanoparticles (SiLNP) with properties that enhance vascular repair and exhibit antitumor activity. In transgenic GFP mouse models, Si5-N14 mediates CRISPR-Cas9 editing. In Lewis lung carcinoma (LLC) tumor mouse models, it leads to the knockdown of vascular endothelial growth factor receptor 2 (VEGFR2), producing antitumor effects. Additionally, in mice with virus-induced lung injury, Si5-N14 facilitates the delivery of fibroblast growth factor-2 (FGF-2) mRNA, promoting vascular repair, oxygenation, and improved lung function. Si5-N14 shows potential for research in tumors, pneumonia, and cardiovascular diseases.Formula:C78H160N6O5Si2Colore e forma:SolidPeso molecolare:1318.31VEGFR2/HDAC1-IN-1
VEGFR2/HDAC1-IN-1 (compound 13) is a potent dual inhibitor of VEGFR-2 and HDAC, with IC50 values of 57.83 nM for VEGFR-2 and 9.82 nM for HDAC.Purezza:98%Colore e forma:Odour SolidMET/PDGFRA-IN-2
<p>MET/PDGFRA-IN-2 (compound 8h) serves as an inhibitor of MET and PDGFRA proteins, promoting apoptosis in cells and impeding the proliferation of MET-positive</p>Formula:C29H29N7OPurezza:98%Colore e forma:SolidPeso molecolare:491.59EGFR/VEGFR2-IN-5
EGFR/VEGFR2-IN-5 (Compound 14) is an orally active dual inhibitor of EGFR and VEGFR2, exhibiting an IC50 value of 1.15 µM for VEGFR2 and 0.28 µM for EGFRT790M. This compound demonstrates significant anticancer activity.Formula:C17H15N7O5SColore e forma:SolidPeso molecolare:429.41PKM2/PDK1-IN-1
PKM2/PDK1-IN-1, a shikonin derivative, dual inhibitor of PKM2/PDK1, halts NSCLC growth, triggers apoptosis, and boosts ROS affecting cell death pathways.Formula:C36H43NO7S3Colore e forma:SolidPeso molecolare:697.92SOS1/EGFR-IN-2
SOS1/EGFR-IN-2 (Compound 4) functions as a dual inhibitor of SOS1 and EGFR, exhibiting IC50 values of 8.3 and 14.6 nM, respectively. It demonstrates significant antiproliferative effects on cancer cells harboring various KRAS mutations.Formula:C25H29F3N4O3Colore e forma:SolidPeso molecolare:490.52MY-1576
MY-1576 is a FAK inhibitor with an IC50 of 8 nM. It activates the Hippo pathway, thereby inhibiting YAP/TAZ regulation. Additionally, MY-1576 effectively suppresses tumor growth in the KYSE30 xenograft mouse model, demonstrates good safety, and efficiently downregulates FAK autophosphorylation and YAP/TAZ levels in vivo.Formula:C25H29ClN8O2Colore e forma:SolidPeso molecolare:509OK2
OK2, a specific inhibitor of the CCN2/EGFR interaction, effectively disrupts this interaction by binding to the CT domain of CCN2.Formula:C42H62N14O9Purezza:98%Colore e forma:SolidPeso molecolare:907.03Cetuximab (PBS)
Cetuximab (PBS) is a human IgG1 monoclonal antibody that inhibits the epidermal growth factor receptor (EGFR), with a dissociation constant (Kd) of 0.201 nM for EGFR as measured by the SPR method. It exhibits potent antitumor activity.Colore e forma:Odour LiquidJAK-IN-15
CAS:<p>JAK-IN-15 is a JAK inhibitor. WO2016119700A1 (Compound 15).</p>Formula:C22H23FN4O3SColore e forma:SolidPeso molecolare:442.51MS9427
CAS:<p>MS9427: PROTAC EGFR degrader, 7.1 nM (WT), 4.3 nM (L858R); targets mutant via UPS and autophagy; inhibits NSCLC cell growth; anticancer research.</p>Formula:C48H58ClFN8O12Colore e forma:SolidPeso molecolare:993.47EGFR-IN-162
<p>EGFR-IN-162 (compound 20) is an effective EGFR inhibitor that enhances both early and late apoptosis (EGFR) as well as necrosis (necrosis). It shows potential for use in breast cancer research.</p>Formula:C27H31N3O2Colore e forma:SolidPeso molecolare:429.24163CG-3-246
<p>CG-3-246 is a dual inhibitor targeting FLT3 and BCL-2, with dissociation constants (Kd) of 63 nM and 4.25 nM, respectively. This compound plays a significant role in acute myeloid leukemia research.</p>Formula:C64H73ClN14O10SColore e forma:SolidPeso molecolare:1265.87
